Ana Recober1, Andrew F Russo. 1. Departments of Neurology, University of Iowa, Iowa City, Iowa 52242, USA. ana-recober@uiowa.edu
Abstract
PURPOSE OF REVIEW: This review includes the most relevant and recent studies on the biology of calcitonin gene-related peptide (CGRP) as it pertains to primary headaches and particularly to migraine. Especial attention was given to those published within the last year. RECENT FINDINGS: The development of CGRP receptor antagonists is discussed in detail, as well as recent advances in our understanding of CGRP actions in migraine. Finally, other important functions of CGRP outside of the nervous system are briefly discussed. SUMMARY: The advent of CGRP receptor antagonists as a novel therapy for migraine attacks may represent a new era in the acute management of migraine. More than a simple addition to the currently available treatments, this group of drugs may become an outstanding option for patients with cardiovascular disease, given the lack of associated vasoconstriction. Furthermore, nonpeptide CGRP receptor antagonists, CGRP antibodies and CGRP-binding RNA-Spiegelmer are valuable research tools that will further advance our understanding of migraine pathophysiology.
PURPOSE OF REVIEW: This review includes the most relevant and recent studies on the biology of calcitonin gene-related peptide (CGRP) as it pertains to primary headaches and particularly to migraine. Especial attention was given to those published within the last year. RECENT FINDINGS: The development of CGRP receptor antagonists is discussed in detail, as well as recent advances in our understanding of CGRP actions in migraine. Finally, other important functions of CGRP outside of the nervous system are briefly discussed. SUMMARY: The advent of CGRP receptor antagonists as a novel therapy for migraine attacks may represent a new era in the acute management of migraine. More than a simple addition to the currently available treatments, this group of drugs may become an outstanding option for patients with cardiovascular disease, given the lack of associated vasoconstriction. Furthermore, nonpeptide CGRP receptor antagonists, CGRP antibodies and CGRP-binding RNA-Spiegelmer are valuable research tools that will further advance our understanding of migraine pathophysiology.
Authors: Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko Journal: N Engl J Med Date: 2004-03-11 Impact factor: 91.245
Authors: Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner Journal: Lancet Date: 2008-11-25 Impact factor: 79.321
Authors: Marcelo E Bigal; Alan M Rapoport; Stephen D Silberstein; Sarah Walter; Richard J Hargreaves; Ernesto Aycardi Journal: CNS Drugs Date: 2018-11 Impact factor: 5.749
Authors: Guanglin Luo; Ling Chen; Charles M Conway; Rex Denton; Deborah Keavy; Michael Gulianello; Yanling Huang; Walter Kostich; Kimberley A Lentz; Stephen E Mercer; Richard Schartman; Laura Signor; Marc Browning; John E Macor; Gene M Dubowchik Journal: ACS Med Chem Lett Date: 2012-02-27 Impact factor: 4.345
Authors: Asha Nair; Manuela Simonetti; Nicol Birsa; Michel D Ferrari; Arn M J M van den Maagdenberg; Rashid Giniatullin; Andrea Nistri; Elsa Fabbretti Journal: Mol Pain Date: 2010-08-24 Impact factor: 3.395